Vernalis to receive payment from Lundbeck

Vernalis Plc said it has achieved a research milestone in its drug discovery collaboration with H. Lundbeck A/S, triggering a payment of £0.3 million. The UK company is identifying candidate compounds targeting the kinase, LRRK2.